A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Clinical trial NCT06161571 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06161571
- Sponsor
- Akero Therapeutics, Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-10
- Primary completion
- 2026-03-03
- Enrollment
- 700
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.